Document:

EX-10.1

 Exhibit 10.1 

EMPLOYMENT AGREEMENT 

EMPLOYMENT AGREEMENT, dated as of July 26, 2018 (the “Agreement”), between IQVIA Holdings Inc. (the
“Company”) and Ari Bousbib (the “Executive”). 
 WHEREAS, the Company desires that the Executive continue
to serve the Company as its Chief Executive Officer and President on the terms and conditions set forth herein. 
 NOW, THEREFORE, in
consideration of the premises and mutual covenants herein and for other good and valuable consideration, the parties agree as follows: 
 1.
General. 
 This Agreement shall govern the terms and conditions of the Executive’s continued employment with the Company on and
after July 26, 2018 (the “Effective Date”). The Executive’s principal place of employment shall continue to be at the Company’s offices in New York, New York and Parsippany, New Jersey. 

2. Employment, Duties and Agreements. 

(a)    Position. The Company hereby agrees to continue to employ the Executive as its Chief Executive Officer and
President, and the Executive hereby agrees to continue in such position and agrees to serve the Company in such capacities during the employment period fixed by Section 4 hereof (the “Employment Period”). During the Employment
Period, subject to the requirements of applicable law (including, without limitation, any rules or regulations of any exchange on which the common stock of the Company is listed, if applicable), the Company agrees to propose to the shareholders of
the Company at each applicable annual meeting occurring during the Employment Period the re-election of the Executive as a member of the Board of Directors of the Company (the “Board”) and the
Executive shall so serve if re-elected. In addition, and without further compensation, the Executive shall serve as a director and/or officer of one or more of the Company’s Affiliates (as defined below)
if so elected or appointed from time to time. In the event the Executive’s employment with the Company terminates for any reason, the Executive’s membership on the Board and the Executive’s service as a director and/or officer of the
Company and any of the Company’s Affiliates shall also terminate, and the Executive shall be deemed to resign from the Board and from all such director and officer positions immediately upon such termination of employment, in each case, unless
otherwise agreed in writing by the Company and the Executive. The Executive shall have such duties and responsibilities as are consistent with the Executive’s position and as may be reasonably assigned by the Board from time to time. During the
Employment Period, the Executive shall report to, and shall act in accordance with, all reasonable instructions and directions of the Board and all applicable policies and rules of the Company. 

(b)    Duties. During the Employment Period, excluding any periods of vacation and sick leave to which the
Executive is entitled, the Executive shall devote his full working time, energy and attention, and his best efforts, abilities, experience and talent, to the performance of his duties and responsibilities hereunder and shall faithfully and
diligently endeavor to promote the business and best interests of the Company. 

 (c)    Outside Activities. During the Employment Period, the Executive
may not, without the prior written consent of the Board, directly or indirectly, operate, participate in the management, operations or control of, or act as an executive, officer, consultant, agent or representative of, any type of business or
service (other than as an executive of the Company); provided, that it shall not be a violation of the foregoing for the Executive to (i) manage his personal, familial, real estate, financial and legal affairs or trusts or
(ii) serve as a director of (or similar position with) an educational, charitable, community, civic, religious or similar type of organization, with the approval of the Board, so long as, in each such case, such activities do not interfere with
the performance of his duties and responsibilities to the Company as provided hereunder; and provided, further, that the Board shall not unreasonably withhold consent to the Executive serving as a director on the board of a company
whose activities are not in competition, directly or indirectly, with those of the Company and the amount of time and attention required of the Executive to satisfy his obligations as such a director are not reasonably likely to, and do not, detract
from the execution of his duties and responsibilities hereunder in any material respect. Such consent is hereby granted for the Executive to continue as a member of the board of directors of The Home Depot, Inc. 

3. Compensation. 

(a)    Base Salary. As compensation for the agreements made by the Executive herein and the performance by the
Executive of his obligations hereunder, during the Employment Period, the Company shall pay the Executive, pursuant to its normal and customary payroll procedures, a base salary at the rate of $1,600,000 per annum (the “Base
Salary”). The Executive’s Base Salary shall be reviewed at least annually by the Board or the Leadership Development and Compensation Committee of the Board (the “Compensation Committee”) for increase only. 

(b)    Annual Bonus. During the Employment Period, the Executive shall be eligible, through participation in the
Company’s annual bonus plan or program for its executives generally, as in effect from time to time (the “Bonus Plan”), to earn an annual bonus (the “Annual Bonus”) in each fiscal year during the Employment
Period, with a target Annual Bonus of 200% of Base Salary, with the actual amount of the Annual Bonus paid to the Executive based on the achievement of performance objectives approved by the Board or the Compensation Committee (it being understood
that the Executive may be eligible to earn an Annual Bonus in excess of the target Annual Bonus if performance for a fiscal year exceeds target performance to the extent determined by the Board or the Compensation Committee in accordance with the
terms of the Bonus Plan). In addition, the Board or the Compensation Committee may, in its discretion, increase the Executive’s target Annual Bonus opportunity as a percentage of Base Salary. To the extent so earned, any Annual Bonus shall be
paid in accordance with the Bonus Plan. 
 (c)    Equity Awards. During the Employment Period the Executive shall
be eligible to receive equity and equity-based awards in the discretion of the Board or the Compensation Committee and on such terms and conditions as determined by the Board or the Compensation Committee. Any equity and equity-based awards granted
to the Executive, whether before or after the Effective Date, shall be governed by the terms and conditions of the applicable Company equity incentive plan(s), as may be in effect from time to time, and the award agreements governing such equity or
equity-based awards (any such plan and award agreements, collectively, the “Equity Agreements”). 

  
 2 

 (d)    Benefits. During the Employment Period, except as specifically
provided herein, (i) the Executive shall be entitled to participate in all savings and retirement plans, practices, policies and programs of the Company that are made available generally to other senior executive officers of the Company,
including the IMS Health Retirement Plan, the IMS Health Savings Equalization Plan, and the IMS Health Retirement Excess Plan (in each case, or any successor plan), but excluding the IMS Health Defined Contribution Executive Retirement Plan and
those plans maintained for legacy employees of Quintiles Transnational Holdings Inc., (ii) the Executive shall be entitled to be reimbursed up to $50,000 per year in the aggregate for home security and financial and estate planning expenses, tax
preparation services and executive physical exams, (iii) the Executive shall be entitled to use a Company-leased automobile and be reimbursed for operating expenses relating to such automobile, (iv) the Executive shall be entitled to use
the Company’s aircraft for business use and for up to 150 hours per year of personal use, subject, in the case of personal use, to the business needs of the Company, and the Executive’s family may accompany the Executive on any such
travel, and (v) the Executive and/or the Executive’s family, as the case may be, shall be eligible for participation in, and shall receive all benefits under, all of the Company’s
welfare benefit plans, practices, policies and programs, including, but not limited to, its disability and health insurance plans and vacation/sick/personal days provided by the Company, which are made available generally to other senior executive
officers of the Company (for the avoidance of doubt, such plans, practices, policies or programs shall not include any plan, practice, policy or program which provides benefits in the nature of severance or continuation pay), subject, in each case,
to the terms and conditions of the applicable Company plan, practice, policy or program and subject, in the case of any reimbursement, to the Company’s policies and procedures now in force or as such policies and procedures may be modified with
respect to all senior executive officers of the Company. 
 (e)    Reimbursement of Business Expenses. The
Company shall reimburse the Executive for all reasonable business expenses upon the presentation of statements of such expenses in accordance with the Company’s policies and procedures now in force or as such policies and procedures may be
modified with respect to all senior executive officers of the Company. 
 (f)    Section 280G. If all, or any
portion, of the payments provided under this Agreement, either alone or together with other payments or benefits which the Executive receives or is entitled to receive from the Company or any of its Affiliates (as defined below), would constitute an
“excess parachute payment” within the meaning of Section 280G of the Internal Revenue Code of 1986, as amended (the “Code”), then the Executive shall be entitled to receive (i) an amount limited so that no
portion thereof shall fail to be tax deductible under Section 280G of the Code (the “Limited Amount”), or (ii) if the amount otherwise payable or to be provided to the Executive (without regard to clause (i)) reduced by
the excise tax imposed by Section 4999 of the Code and all applicable federal, state and local employment and income taxes (all computed at the highest applicable marginal rate) is greater than the Limited Amount, the amount otherwise payable
to the Executive. If it is determined that the Limited Amount will maximize the Executive’s after-tax proceeds, payments and benefits shall be reduced to equal the Limited Amount in the following order:
(i) first, by reducing cash severance payments (if and to the extent such severance payments are deemed to be “parachute payments” within the meaning of Section 280G of the Code), (ii) second, by reducing other payments and
benefits to which Q&A 24(c) of Section 1.280G-1 of the Treasury Regulations does not apply, and (iii) finally, by reducing all 

  
 3 

 
remaining payments and benefits (in the case of clauses (ii) and (iii), starting with those payments and benefits for which the amount required to be taken into account under
Section 280G of the Code is the greatest). All determinations made pursuant this Section 3(f) will be made at the Company’s expense by the independent public accounting firm most recently serving as the Company’s outside auditors
or such other accounting or benefits consulting group or firm as the Company may designate. 
 4. Employment Period. 

The Employment Period shall terminate on the third anniversary of the Effective Date,
provided that on the third anniversary of the Effective Date and on each one-year anniversary thereafter, the Employment Period shall automatically be extended for additional one-year periods unless either party provides the other party with notice of non-renewal at least sixty (60) days before any such anniversary (the anniversary date on
which the Employment Period terminates shall be referred to herein as the “Scheduled Termination Date”). For greater clarity, a non-renewal notice given as contemplated in this Section 4
shall be a Notice of Termination (as defined below) of employment, effective on the Scheduled Termination Date, for all purposes of this Agreement, and if given by the Company shall give rise to an involuntary separation from service (within the
meaning of Section 409A of the Code) on the Scheduled Termination Date. If such Notice of Termination is given by the Company (an “Expiration Termination”), the Executive shall be entitled to receive the payments as set forth
in Section 6(a) below. If such Notice of Termination is given by the Executive, the Executive shall only be entitled to receive the payments set forth in Section 6(c) below. 

Notwithstanding the foregoing, the Executive’s employment hereunder may be terminated during the Employment Period prior to the Scheduled
Termination Date upon the earliest to occur of any one of the following events (at which time the Employment Period shall be terminated): 

(a)    Death. The Executive’s employment hereunder shall terminate upon his death. 

(b)    Disability. The Company shall be entitled to terminate the Executive’s employment hereunder for
“Disability” if, as a result of the Executive’s incapacity due to physical or mental illness or disability, the Executive shall have been unable to perform his duties hereunder for a period of six (6) consecutive months,
and within thirty (30) days after written Notice of Termination is thereafter given the Executive shall not have returned to the full-time performance of his duties hereunder. 

(c)    Cause. The Company may terminate the Executive’s employment hereunder for Cause. For purposes of this
Agreement, the term “Cause” shall mean: (i) a material breach by the Executive of this Agreement or any agreement governing the terms of any equity or equity incentive award granted to the Executive, (ii) a material breach
by the Executive of any written policy of the Company or any of its Affiliates that is damaging to the financial condition or reputation of the Company or its Affiliates, (iii) the willful failure by the Executive to reasonably and
substantially perform his duties to the Company or any of its Affiliates, which failure is materially damaging to the financial condition or reputation of the Company or such Affiliate, (iv) the Executive’s willful misconduct or gross
negligence which is injurious to the Company or any of its Affiliates, or (v) the commission by the Executive of a felony or other serious crime involving 

  
 4 

 
moral turpitude. In the case of clauses (i) and (ii) above, the Company shall permit the Executive up to fifteen (15) days to cure such breach or failure if reasonably susceptible to
cure. If, subsequent to the Executive’s termination of employment for other than Cause, it is determined that the Executive’s employment could have been terminated for Cause, the Executive’s employment shall be deemed to have been
terminated for Cause retroactively to the date the events giving rise to such Cause occurred. For purposes of this Agreement, “Affiliates” means all persons and entities directly or indirectly controlling, controlled by or under
common control with respect to a specified person or entity, where control shall mean the possession, direct or indirect, of the power to direct or cause the direction of the management and policies of such person or entity, whether through the
ownership of voting securities, by contract or otherwise. 
 (d)    Without Cause. The Company may terminate the
Executive’s employment hereunder during the Employment Period without Cause by giving a Notice of Termination (as defined in Section 5 below). 

(e)    Voluntarily. The Executive may voluntarily terminate his employment hereunder, without Good Reason,
including as a result of Retirement, provided that the Executive provides the Company with notice of his intent to terminate his employment at least thirty (30) days, or, in the case of Retirement, at least one hundred and twenty
(120) days, in advance of the Date of Termination (as defined in Section 5 below) in accordance with Section 5(a) below. 

(f)    For Good Reason. The Executive may terminate his employment hereunder for Good Reason, provided the
Executive complies with all requirements of such a termination as provided hereunder and in Section 5 below. For purposes of this Agreement, “Good Reason” shall mean any of the following events or conditions occurring without
the Executive’s express prior written consent, provided that the Executive shall have given written notice of such event or condition within a period not to exceed twenty (20) days of the Executive’s initial knowledge of the first
existence of such event or condition, the Company shall not have remedied such event or condition within thirty (30) days after receipt of such notice and the Executive shall have actually terminated his employment within thirty (30) days
thereafter: (i) a materially adverse alteration in the nature or status of the Executive’s title, duties, responsibilities (including reporting responsibilities) or the conditions of employment, provided, that a failure to re-appoint the Executive as Chairman of the Board or the Executive’s failure to be re-elected to the Board by the Company’s shareholders shall not constitute Good
Reason hereunder, (ii) a material reduction in the Executive’s annual base salary or target annual bonus opportunity, (iii) a change of thirty-five (35) miles or more in the Executive’s principal place of employment, except
for required travel on business to an extent substantially consistent with the Executive’s business travel obligations, (iv) the failure by the Company to pay to the Executive any material portion of the Executive’s compensation due
hereunder, or (v) a material breach by the Company of this Agreement. 
 5. Termination Procedure. 

(a)    Notice of Termination. Any termination of the Executive’s employment by the Company or by the Executive
during or upon the expiration of the Employment Period (other than a termination on account of the death of Executive) shall be communicated by written “Notice of Termination” to the other party hereto in accordance with
Section 10(b) of this Agreement. 

  
 5 

 (b)    Date of Termination. For purposes of this Agreement,
“Date of Termination” shall mean (i) if the Executive’s employment is terminated by his death, the date of his death, (ii) if the Executive’s employment is terminated pursuant to Section 4(c) of this
Agreement, on the date the Executive receives Notice of Termination from the Company, (iii) if the Executive voluntarily terminates his employment without Good Reason, the date specified in the notice given pursuant to Section 4(e) herein,
which shall not be less than thirty (30) days after the Notice of Termination (or one hundred and twenty (120) days thereafter, in the case of Retirement), (iv) if the Executive terminates his employment for Good Reason, the date specified
in the notice given by the Executive of the event constituting Good Reason, which shall comply with the time periods and procedural requirements provided in Section 4(f) of this Agreement, and (v) if the Executive’s employment is
terminated for any other reason, the date on which a Notice of Termination is given or any later date (within thirty (30) days, or any alternative time period agreed upon by the parties, after the giving of such notice) set forth in such Notice
of Termination, including the Scheduled Termination Date, as applicable. 
 6. Termination Payments. 

(a)    Without Cause, For Good Reason or an Expiration Termination. In the event the Employment Period terminates
under this Agreement as a result of any of (x) the Company terminating the Executive’s employment without Cause, (y) the Executive terminating his employment for Good Reason, or (z) an Expiration Termination, the Company shall
pay the Executive (A) within thirty (30) days following the Date of Termination, the Executive’s accrued but unpaid Base Salary through the Date of Termination; the Annual Bonus earned for the year prior to the Date of Termination if
the Date of Termination occurs after year end but before the Annual Bonus is paid; unreimbursed expenses due under Section 3(e) of this Agreement; and vested rights under compensation and/or benefits plans (all to the extent not theretofore
paid) (collectively, the “Accrued Benefits”) and (B) two (2) times the sum of Executive’s Base Salary and target Annual Bonus, payable in equal installments over a twenty four (24)-month period in accordance with the
Company’s standard payroll practices, payable as provided in Section 6(e) below. In addition, (I) any equity or equity-based awards (or portions thereof) that are granted to the Executive after the Effective Date that are subject
solely to time-based vesting conditions (collectively, the “Time Awards”), to the extent then unvested, shall vest in full as of the Date of Termination and, if applicable, shall remain exercisable until the latest date on which
such awards may be exercised under the applicable Equity Agreements, determined without regard to the Executive’s termination of employment, and (II) any equity or equity-based awards (or portions thereof) that are granted to the Executive
after the Effective Date that are subject to performance-based vesting conditions (the “Performance Awards”), to the extent then unvested, shall be eligible to vest following the end of the applicable performance period based on
actual performance. The payments and benefits provided under this Section 6(a) (other than clause 6(a)(A)), including any accelerated vesting as provided herein, are subject to and conditioned upon the (i) Executive executing a timely and
valid general release and waiver (in substantially the form set forth in Exhibit A) (the “Release”), waiving all claims the Executive may have against the Company its successors, assigns, Affiliates, executives, officers and
directors, (ii) the Executive delivering the executed Release to the Company within the time period specified by the Company following the Date of Termination, (iii) such Release and the waiver contained therein becoming effective in
accordance with their respective terms, and (iv) the Executive’s compliance with Section 9 of this Agreement (the conditions described in (i), (ii), (iii) and (iv), the “Termination Conditions”). For

  
 6 

 
the avoidance of doubt, upon a termination of the Employment Period without Cause, as a result of Good Reason, or due to an Expiration Termination, the Executive shall not be entitled to any
other compensation or benefits not expressly provided for in this Section 6(a), regardless of the time that would otherwise remain in the Employment Period had the Employment Period not been so terminated. Except as provided in this
Section 6(a), and except for any vested benefits under any tax qualified pension plans of the Company, any rights under the Equity Agreements, and continuation of health insurance benefits on the terms and to the extent required by
Section 4980B of the Code, and Section 601 of the Employee Retirement Income Security Act of 1974, as amended (which provisions are commonly known as “COBRA”), or such other similar law or regulation as may be applicable
to the Executive or the Company with respect to the Executive, the Company shall have no additional obligations under this Agreement. 

(b)    Change in Control. In the event the Employment Period terminates under this Agreement under circumstances
described in Section 6(a) above except that such termination occurs within twenty-four (24) months following a transaction or event constituting a “change in control event” of the Company under Section 409A of the Code, the
Company shall provide the Executive with all payments and benefits described in Section 6(a) above except that the amounts payable under clause (B) of the first sentence of Section 6(a) shall be payable in a lump sum following such
termination at the time provided in Section 6(e) below rather than over a twenty four (24)-month period, and the Time Awards and the Performance Awards, to the extent then unvested, shall vest in full upon such termination, with the Performance
Awards vesting based on a deemed achievement of target performance, and, if applicable, the Time Awards remaining exercisable until the latest date on which such awards may be exercised under the applicable Equity Agreements, determined without
regard to the Executive’s termination of employment. 
 (c)    Cause or Voluntarily Other than for Good Reason
(including Retirement). If the Executive’s employment is terminated during the Employment Period by the Company for Cause or voluntarily by the Executive other than for Good Reason, the Company shall pay the Executive within thirty
(30) days following the Date of Termination the Accrued Benefits. If the Executive terminates his employment due to his Retirement, subject to compliance by the Executive with the Termination Conditions, (I) the Time Awards, to the extent
then unvested, shall vest as of the Date of Termination as to a prorated number of the shares subject to the portion of each such Time Award that would vest on the next regularly scheduled vesting date, prorated to reflect the number of whole months
the Executive was employed following the most recent vesting date prior to the Date of Termination (or the date of grant, if there has not been a vesting date) over the number of whole months from the most recent vesting date prior to the Date of
Termination (or the date of grant, if there has not been a vesting date) until the next regularly scheduled vesting date of such Time Award and, if applicable, shall remain exercisable until the latest date on which such awards may be exercised
under the applicable Equity Agreements, determined without regard to the Executive’s termination of employment, and (II) the Performance Awards, to the extent then unvested, shall be eligible to vest following the end of the applicable
performance period based on actual performance, with the number of shares subject to such awards that vest based on performance pro rated to reflect the number of whole months the Executive was employed during the applicable performance period over
the number of whole months in the applicable performance period. Except as provided in this Section 6(c), and except for any vested benefits under any tax qualified pension plans of the Company, any rights under the Equity Agreements, and
continuation of health insurance benefits on the terms and to the extent required by COBRA, or such other 

  
 7 

 
similar law or regulation as may be applicable to the Executive or the Company with respect to the Executive, the Company shall have no additional obligations under this Agreement. For purposes
of this Agreement, “Retirement” shall mean a permanent retirement from active employment with the Company (other than at a time when Cause exists) after attaining age sixty-two (62) with
at least five (5) years of employment with the Company or its subsidiaries. 
 (d)    Disability or Death.
If the Executive’s employment is terminated during the Employment Period as a result of the Executive’s death or by the Company due to his Disability, the Company shall pay the Executive or the Executive’s estate, as the case may be,
within thirty (30) days following the Date of Termination, the Accrued Benefits. In addition, the Time Awards and Performance Awards, to the extent then unvested, shall vest in full upon such termination, with Performance Awards vesting based
on a deemed achievement of target performance, and, if applicable, the Time Awards remaining exercisable until the latest date on which such awards may be exercised under the applicable Equity Agreements, determined without regard to the
Executive’s termination of employment, subject, in the case of a termination by the Company due to the Executive’s Disability, to compliance by the Executive (or his guardian or authorized representative, in the case of the Release) with
the Termination Conditions. Except as provided in this Section 6(d), and except for any vested benefits under any tax qualified pension plans of the Company, any rights under the Equity Agreements, and continuation of health insurance benefits
on the terms and to the extent required by COBRA, or such other similar law or regulation as may be applicable to the Executive or the Company with respect to the Executive, the Company shall have no additional obligations under this Agreement. 

(e)    Release. Subject to Section 7(a) of this Agreement, any cash severance payments due under
Section 6(a) or 6(b) of this Agreement will be paid or provided, or will begin to be paid or provided, on the first payroll date following the date the Release becomes irrevocable (the “Release Date”), with all payments and
benefits that would have otherwise been made prior to the Release Date paid or provided on such date. In the case of any equity or equity-based award that vests (or remains eligible to vest) pursuant to Section 6(a), 6(b), 6(c) or 6(d) of this
Agreement, (i) if the award requires exercise, the portion of the award that vests pursuant to such Section shall not become exercisable until the Release Date; and (ii) if the award requires the delivery of cash or shares upon vesting,
such cash or shares shall be delivered as soon as administratively practicable after the Release Date, but in no event later than (x) sixty (60) days following the Termination Date for any equity or equity-based award that is a Time Award and
(y) for any Performance Award, as soon as reasonably practicable following the vesting date of such Performance Award, but in no event later than the March 15th of the year following the year
in which the performance period ends, as set forth in the agreement evidencing such award (or any earlier date, after vesting, as may be required to avoid characterization as non-qualified deferred
compensation under Section 409A of the Code, to the extent applicable), in each case, notwithstanding any contrary provision in the equity compensation plan under which such award was granted or in the agreement evidencing such
award.    Notwithstanding the foregoing and subject to Section 7(a) of this Agreement, to the extent required by Section 409A of the Code, if the Executive’s (or his guardian’s or authorized
representative’s) period for considering the Release spans two (2) calendar years, then any payments or benefits that are subject to such release shall in all events be made in the second calendar year. 

  
 8 

 (f)    Treatment of Equity. To the extent not specifically provided
for herein, the vesting and exercisability of equity and equity-based awards (if any) held by the Executive at termination, and all other terms of such equity and equity-based awards (if any), shall be governed by the Equity Agreements. 

7. Timing of Payments and Section 409A. 

(a)    Notwithstanding anything to the contrary in this Agreement, if at the time of the Executive’s termination of
employment, the Executive is a “specified employee,” as defined below, any and all amounts payable under Section 6 above on account of such separation from service that would (but for this provision) be payable within six
(6) months following the date of termination, shall instead be paid on the next business day following the expiration of such six (6) month period or, if earlier, the date of the Executive’s death; except (A) to the extent of
amounts that do not constitute a deferral of compensation within the meaning of Treasury regulation Section 1.409A-1(b) (including without limitation by reason of the safe harbor set forth in Section 1.409A-1(b)(9)(iii), as determined by the Company in its reasonable good faith discretion); (B) benefits which qualify as excepted welfare benefits pursuant to Treasury regulation Section 1.409A-1(a)(5); or (C) other amounts or benefits that are not subject to the requirements of Section 409A of the Code. 

(b)    For purposes of this Agreement, all references to “termination of employment” and correlative phrases
shall be construed to require a “separation from service” (as defined in Section 1.409A-1(h) of the Treasury regulations after giving effect to the presumptions contained therein), and the term
“specified employee” means an individual determined by the Company to be a specified employee under Treasury regulation Section 1.409A-1(i). 

(c)    Each payment made under this Agreement shall be treated as a separate payment and the right to a series of
installment payments under this Agreement is to be treated as a right to a series of separate payments. 
 (d)    Any
reimbursements under this Agreement that would constitute nonqualified deferred compensation subject to Section 409A of the Code shall be subject to the following additional rules: (i) no reimbursement of any such expense shall affect the
Executive’s right to reimbursement of any such expense in any other taxable year; (ii) reimbursement of the expense shall be made, if at all, promptly, but not later than the end of the calendar year following the calendar year in which
the expense was incurred; and (iii) the right to reimbursement shall not be subject to liquidation or exchange for any other benefit. 

8. Legal Fees; Indemnification; Officers’ Liability Insurance. 

(a)    In the event of any contest or dispute between the Company and the Executive with respect to this Agreement or the
Executive’s employment hereunder, each of the parties shall be responsible for its respective legal fees and expenses. 

(b)    The Executive shall be indemnified for all acts and omissions to act to the maximum extent permitted under the
Company’s charter, by-laws and under applicable law. During the Employment Period and for six (6) years thereafter, the Executive shall be entitled to the same officers’ and directors’
liability insurance coverage that the Company provides generally 

  
 9 

 
to its other members of the Board (and if none, then to its officers), as may be amended from time to time for such directors and officers. 

9. Non-Competition and Non-Disclosure; Executive
Cooperation; Non-Disparagement. 

(a)    Non-Competition. Without the consent in writing of the Board, the
Executive will not, at any time during the Employment Period and for the two years following the Employment Period, acting alone or in conjunction with others, directly or indirectly (i) engage (either as owner, investor, partner, stockholder,
employer, employee, consultant, advisor, or director) in any business in which he has been directly engaged on behalf of the Company or any Affiliate, or has supervised as an executive thereof, during the last two years prior to such termination, or
which was engaged in or planned by the Company or an Affiliate at the time of such termination, in any geographic area in which such business was conducted or planned to be conducted; (ii) induce, or attempt to induce, any customers of the
Company or any of its Affiliates with whom the Executive has had contacts or relationships, directly or indirectly, during and within the scope of his employment with the Company or any of its Affiliates, to curtail or cancel their business with the
Company or any such Affiliate; (iii) induce, or attempt to influence, any employee of the Company or any of its Affiliates to terminate employment; or (iv) solicit, hire or retain as an employee or independent contractor, or assist any
third party in the solicitation, hire, or retention as an employee or independent contractor, any person who during the previous 12 months was an employee of the Company or any Affiliate. The provisions of subparagraphs (i), (ii), (iii), and
(iv) above are separate and distinct commitments independent of each of the other subparagraphs. It is agreed that the ownership of not more than one percent (1%) of the equity securities of any company having securities listed on an exchange
or regularly traded in the over-the-counter market shall not, of itself, be deemed inconsistent with clause (i) of this Section 9(a). 

(b)    Non-Disclosure. The Executive shall not, at any time during the
Employment Period and thereafter (including following the Executive’s termination of employment for any reason), disclose, use, transfer, or sell, except in the course of employment with or other service to the Company, any proprietary
information, secrets, organizational or employee information, or other confidential information belonging or relating to the Company, any of its Affiliates or customers so long as such information has not otherwise been disclosed or is not otherwise
in the public domain, except as required by law or pursuant to legal process. In addition, upon termination of employment for any reason, the Executive will return to the Company or its Affiliates all documents and other media containing information
belonging or relating to the Company or its Affiliates; provided, however, that the Executive may keep a copy of his contacts and/or rolodex and any compensatory or other agreements that are personal to the Executive. Notwithstanding the foregoing
or anything else to the contrary, (a) nothing contained in this Agreement or any other agreement containing confidentiality provisions or other restrictive covenants in favor of the Company or any of its Affiliates shall be construed to limit,
restrict or in any other way affect the Executive’s communicating with any governmental agency or entity, or communicating with any official or staff person of a governmental agency or entity, concerning matters relevant to the governmental
agency or entity and (b) the Executive will not be held criminally or civilly liable under any federal or state trade secret law for disclosing a trade secret (i) in confidence to a federal, state, or local government official, either
directly or indirectly, or to an attorney, solely for the purpose of reporting or investigating a suspected violation of law, or (ii) 

  
 10 

 
in a complaint or other document filed under seal in a lawsuit or other proceeding; provided that notwithstanding this immunity from liability, Executive may be held liable if Executive
unlawfully accesses trade secrets by unauthorized means. 
 (c)    Ownership of Work. The Executive will promptly
disclose in writing to the Company all inventions, discoveries, developments, improvements and innovations (collectively referred to as “Inventions”) that the Executive has conceived or made during the Employment Period;
provided, however, that in this context “Inventions” are limited to those which (i) relate in any manner to the existing or contemplated business or research activities of the Company or its Affiliates; (ii) are
suggested by or result from the Executive’s work at the Company or its Affiliates (including any predecessors); or (iii) result from the use of the time, materials or facilities of the Company or its Affiliates. All Inventions will be the
Company’s property rather than the Executive’s. Should the Company request it, the Executive agrees to sign any document that the Company may reasonably require to establish ownership in any Invention. 

(d)    Cooperation With Regard to Litigation. The Executive agrees to cooperate with the Company, during the
Employment Period and thereafter (including following the Executive’s termination of employment for any reason), by making himself available to testify on behalf of the Company or any subsidiary or Affiliate of the Company, in any action, suit,
or proceeding, whether civil, criminal, administrative, or investigative, and to assist the Company, or any subsidiary or Affiliate of the Company, in any such action, suit, or proceeding, by providing information and meeting and consulting with the
Board or its representatives or counsel, or representatives or counsel to the Company, or any subsidiary or Affiliate of the Company, as may be reasonably requested and after taking into account the Executive’s post-termination responsibilities
and obligations. The Company agrees to reimburse the Executive, on an after-tax basis each calendar quarter, for all expenses actually incurred in connection with his provision of testimony or assistance in
accordance with the provisions of Section 7(d) of this Agreement but not later than the last day of the year in which the expense was incurred. 

(e)    Non-Disparagement. Subject to last sentence of Section 9(b) of
this Agreement, the Executive shall not, at any time during the Employment Period and thereafter, make statements or representations, or otherwise communicate, directly or indirectly, in writing, orally, or otherwise, or take any action which may,
directly or indirectly, disparage or be damaging to the Company or its subsidiaries or Affiliates, officers, directors, employees, advisors, businesses or reputations, nor shall any member of the Board, any officer of the Company, or the Senior Vice
President of Human Resources of the Company make any such statements or representations regarding the Executive. Notwithstanding the foregoing, nothing in this Agreement shall preclude the Executive or the Company from making truthful statements
that are required by applicable law, regulation or legal process. The Company agrees that the Executive, in addition to any other remedies available to him, shall be entitled to apply for preliminary and permanent injunctive relief against any
breach of the covenant contained in this subsection (e), without having to post bond. 
 (f)    Enforcement of
Covenants. The Executive acknowledges that he has carefully read and considered all the terms and conditions of this Agreement, including the restraints imposed upon him pursuant to this Section 9. The Executive agrees without reservation
that each of the restraints contained herein is necessary for the reasonable and proper protection of the goodwill, confidential information and other legitimate interests of the Company and its Affiliates; that each

  
 11 

 
and every one of those restraints is reasonable in respect to subject matter, length of time and geographic area; and that these restraints, individually or in the aggregate, will not prevent him
from obtaining other suitable employment during the period in which the Executive is bound by these restraints. The Executive further agrees that he will never assert, or permit to be asserted on his behalf, in any forum, any position contrary to
the foregoing. The Executive further acknowledges that, were he to breach any of the covenants contained in this Section 9, the damage to the Company would be irreparable. The Executive therefore agrees that the Company, in addition to any
other remedies available to it, shall be entitled to apply for preliminary and permanent injunctive relief against any breach or threatened breach by the Executive of any of said covenants, without having to post bond. The parties further agree
that, in the event that any provision of this Section 9 shall be determined by any court of competent jurisdiction to be unenforceable by reason of its being extended over too great a time, too large a geographic area or too great a range of
activities, such provision shall be deemed to be modified to permit its enforcement to the maximum extent permitted by law. The Executive agrees that the period set forth in Section 9(a) above shall be tolled, and shall not run, during any
period of time in which the Executive is in violation of the terms thereof, in order that the Company and its Affiliates shall have all of the agreed upon temporal protection recited herein. No breach of any provision of this Agreement by the
Company, or any other claimed breach of contract or violation of law, or change in the nature or scope of the Executive’s employment relationship with the Company, shall operate to extinguish the Executive’s obligation to comply with this
Section 9. 
 10. Miscellaneous. 

(a)    Survival. The provisions of Section 6, Section 8(b), Section 9 and such provisions of this
Section 10 as apply to give effect to such other surviving provisions shall survive the termination of the Employment Period and any termination or expiration of this Agreement. 

(b)    Any notice or other communication required or permitted under this Agreement shall be effective only if it is in
writing and shall be deemed to be given when delivered personally or four days after it is mailed by registered or certified mail, postage prepaid, return receipt requested or one day after it is sent by a reputable overnight courier service and, in
each case, addressed as follows (or if it is sent through any other method agreed upon by the parties): 
  

If to the Company: 
 IQVIA
Holdings Inc. 
 83 Wooster Heights Road 

Danbury, CT 06810 
 Attn: General
Counsel 
 with a copy (which will not constitute notice) to: 

Ropes & Gray LLP 

Prudential Tower, 800 Boylston Street 

Boston, Massachusetts 02199 

Attention:Renata J. Ferrari, Esq. 

  
 12 

 Email:Renata.Ferrari@ropesgray.com 

Facsimile:617-235-7690 

If to the Executive: 
 Ari Bousbib

 At his last residence address shown on the payroll records of the Company 

with a copy (which will not constitute notice) to: 

Arnold & Porter 
 601
Massachusetts Avenue, NW 
 Washington, DC 20001 

Attn: Joshua F. Alloy 
 Email:
Josh.Alloy@arnoldporter.com 
 Facsmile: 202-942-5999 

or to such other address as any party hereto may designate by notice to the others. 

(c)    This Agreement shall constitute the entire agreement among the parties hereto with respect to the Executive’s
employment hereunder, and supersedes and is in full substitution for any and all prior understandings or agreements with respect to the Executive’s employment (it being understood that any equity and equity-based awards shall be governed by the
relevant Equity Agreements), including, without limitation, the Employment Agreement by and among IMS Health Incorporated, Healthcare Technology Holdings Inc. and the Executive dated August 16, 2010 and the Amended and Restated Employment
Agreement by and among IMS Health Holdings Inc., IMS Health Incorporated and the Executive dated as of February 12, 2014. 

(d)    This Agreement may be amended only by an instrument in writing signed by the parties hereto, and any provision
hereof may be waived only by an instrument in writing signed by the party or parties against whom or which enforcement of such waiver is sought. The failure of any party hereto at any time to require the performance by any other party hereto of any
provision hereof shall in no way affect the full right to require such performance at any time thereafter, nor shall the waiver by any party hereto of a breach of any provision hereof be taken or held to be a waiver of any succeeding breach of such
provision or a waiver of the provision itself or a waiver of any other provision of this Agreement. 
 (e)    The
parties hereto acknowledge and agree that each party has reviewed and negotiated the terms and provisions of this Agreement and has had the opportunity to contribute to its revision. Accordingly, the rule of construction to the effect that
ambiguities are resolved against the drafting party shall not be employed in the interpretation of this Agreement. Rather, the terms of this Agreement shall be construed fairly as to both parties hereto and not in favor or against either party. 

(f)    The parties hereto hereby represent that they each have the authority to enter into this Agreement, and the
Executive hereby represents to the Company that the execution of, and 

  
 13 

 
performance of duties under, this Agreement shall not constitute a breach of or otherwise violate any other agreement to which the Executive is a party. The Executive hereby further represents to
the Company that he will not utilize or disclose any confidential information obtained by the Executive in connection with any former employment with respect to his duties and responsibilities hereunder. 

(g)    This Agreement is binding on and is for the benefit of the parties hereto and their respective successors, assigns,
heirs, executors, administrators and other legal representatives. Neither this Agreement nor any right or obligation hereunder may be assigned by the Executive. 

(h)    The Company shall require any successor (whether direct or indirect, by purchase, merger, consolidation or
otherwise) to all or substantially all of the business and/or assets of the Company to assume this Agreement in the same manner and to the same extent that the Company would have been required to perform it if no such succession had taken place. As
used in the Agreement, “the Company” shall mean both the Company as defined above and any such successor that assumes this Agreement, by operation of law or otherwise. 

(i)    Any provision of this Agreement (or portion thereof) which is deemed invalid, illegal or unenforceable in any
jurisdiction shall, as to that jurisdiction and subject to this Section, be ineffective to the extent of such invalidity, illegality or unenforceability, without affecting in any way the remaining provisions thereof in such jurisdiction or rendering
that or any other provisions of this Agreement invalid, illegal, or unenforceable in any other jurisdiction. If any covenant should be deemed invalid, illegal or unenforceable because its scope is considered excessive, such covenant shall be
modified so that the scope of the covenant is reduced only to the minimum extent necessary to render the modified covenant valid, legal and enforceable. 

(j)    The Company may withhold from any amounts payable to the Executive hereunder all federal, state, city or other
taxes that the Company may reasonably determine are required to be withheld pursuant to any applicable law or regulation, (it being understood, that the Executive shall be responsible for payment of all taxes in respect of the payments and benefits
provided herein). 
 (k)    This Agreement shall be governed by and construed in accordance with the laws of the State
of New Jersey without reference to its principles of conflicts of law. 
 (l)    This Agreement may be executed in
several counterparts, each of which shall be deemed an original, but all of which shall constitute one and the same instrument. An electronic or facsimile of a signature shall be deemed to be and have the effect of an original signature. 

(m)    The headings in this Agreement are inserted for convenience of reference only and shall not be a part of or control
or affect the meaning of any provision hereof. 
 [Remainder of Page Intentionally Left Blank] 

*    *    *    *    * 

  
 14 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

	
	ARI BOUSBIB
	
	/s/ Ari Bousbib
	Name: Ari Bousbib

  

	
	IQVIA HOLDINGS INC.
	
	/s/ Eric Sherbet
	 Name: Eric Sherbet
 Title: Executive Vice
President, General Counsel
           and Secretary

 [Signature Page to Ari Bousbib Employment Agreement] 

  
 15 

 EXHIBIT A 

Form of Release 
 We advise you to consult an
attorney before you sign this Release. You have until the date which is seven (7) days after the Release is signed and returned to IQVIA Holdings Inc. to change your mind and revoke your Release. Your Release shall not become effective or
enforceable until after that date. 
 In consideration for the payments and benefits provided under Section 6 of your Employment Agreement with IQVIA
Holdings Inc. dated as of July 26, 2018 and effective as of such date (the “Agreement”), in connection with the termination of your employment (such payments and benefits collectively, the “Separation
Payments”), by your signature below, you, for yourself and on behalf of your heirs, executors, agents, representatives, successors and assigns, hereby release and forever discharge IQVIA Holdings Inc. and its past and present parent
corporations, subsidiaries, divisions, subdivisions, affiliates and related companies (collectively, the “Company”) and the Company’s past, present and future agents, directors, officers, employees, representatives, assigns,
stockholders, attorneys, insurers, employee benefit programs (and the trustees, administrators, fiduciaries and insurers of such programs), and any other persons acting by, through, under or in concert with any of the persons or entities listed
herein, and their successors (hereinafter “those associated with the Company”), with respect to any and all claims, demands, actions and liabilities, whether in law or equity, which you may have against the Company or those
associated with the Company of whatever kind, including, but not limited to, those arising out of your employment with the Company or the termination of that employment, except as otherwise expressly set forth below. You agree that this Release
covers, but is not limited to, claims arising under the Age Discrimination in Employment Act of 1967, 29 U.S.C. § 621 et seq., Title VII of the Civil Rights Act of 1964, 42 U.S.C. § 2000e et seq., the Americans with Disabilities Act of
1990, 42 U.S.C. § 12101 et seq., the Fair Labor Standards Act, 29 U.S.C. § 201 et seq., the Employee Retirement Income Security Act of 1974, 29 U.S.C. § 1001 et seq., the Family and Medical Leave Act of 1993 and any local, state or
federal law, regulation or order providing workers’ compensation benefits, restricting an employer’s right to terminate employees or otherwise regulating employment, enforcing express or implied employment contracts or requiring an
employer to deal with employees fairly or in good faith, or dealing with discrimination in employment on the basis of sex, race, color, national origin, veteran status, marital status, religion, disability, handicap, or age. You also agree that this
Release includes claims based on wrongful termination of employment, breach of contract (express or implied), tort, or claims otherwise related to your employment or termination of employment with the Company and any claim for attorneys’ fees,
expenses or costs of litigation. For the avoidance of doubt, as it relates to the Company’s agents, directors, officers, employees, representatives, assigns, stockholders, attorneys and insurers, this Release does not include a release of
claims, demands, actions and liabilities that are not related in any way to your relationship with the Company (whether as an employee, officer or director), the termination of that relationship or your equity ownership in the Company. 

This Release covers all claims based on any facts or events, whether known or unknown by you, that occurred on or before the date of this Release. You
expressly waive all rights you might have under any law that is intended to protect you from waiving unknown claims and by your signature 

 
below indicate your understanding of the significance of doing so. Examples of released claims include, but are not limited to: (a) claims that in any way relate to your employment with the
Company, or the termination of that employment, such as claims for compensation, bonuses, commissions, equity awards, lost wages, or unused accrued vacation or sick pay (other than the Separation Payments); (b) claims that in any way relate to the
design or administration of any employee benefit program; (c) claims that you have irrevocable or vested rights to severance or similar benefits (other than the Separation Payments) or to post-employment health or group insurance benefits;
(d) any claim, such as a benefit claim, that was explicitly or implicitly denied before you signed this Release; (e) any claim you might have for extra benefits as a consequence of payments you receive because of signing this Release; or
(f) any claim to attorneys’ fees or other indemnities. Except to enforce this Release, you agree that you will never commence, prosecute, or cause to be commenced or prosecuted any lawsuit or proceeding of any kind against the Company, or
those associated with the Company related to the claims released in this Agreement, in any forum and agree to withdraw with prejudice all such complaints or charges, if any, that you have filed against the Company or those associated with the
Company. Notwithstanding the generality of the foregoing, nothing herein is intended to or shall preclude you or anyone on your behalf from filing a complaint and/or charge with the Equal Employment Opportunity Commission or any similar state or
local government agency and/or filing a related lawsuit and/or cooperating with said agency in any investigation or other proceeding. Nonetheless, you acknowledge that you shall not be entitled to receive any personal relief, recovery, or monies in
connection with any such complaint, charge or related lawsuit brought against the Company or any of those associated with the Company, without regard as to who brought said complaint or charge. 

Anything in this Release to the contrary notwithstanding, this Release does not include a release of: (i) any rights you may have to indemnification and
recovery of officers and directors liability insurance proceeds under any agreement (including, without limitation, the Employment Agreement), law, Company organizational document or policy, or otherwise; (ii) any rights you may have to equity,
compensation or benefits under the Company’s equity, compensation or benefit plans that were accrued and unpaid prior to the date hereof and payable hereafter, except as otherwise provided in your Agreement or claims specifically identified in
this Release; (iii) any rights or claims under the Age Discrimination in Employment Act or any other law, in each case, that arise after you sign this Release; (iv) your right to enforce this Release or any of the foregoing items described
in this paragraph; or (v) your rights and obligations as a shareholder of the Company. 
 By signing this Release, you further agree as follows: 

 

	i.	You have read this Release carefully and fully understand its terms; 

  

	ii.	You have had at least twenty-one (21) days (or at least forty-five (45) days if so indicated by the Company) to consider the terms of the Release; 

 

	iii.	You have seven (7) days from the date you sign this Release to revoke it by written notification to the Company. After this seven (7)-day period, this Release is final and
binding and may not be revoked; 

  
 2 

	iv.	You have been advised to seek legal counsel and have had an opportunity to do so; 

  

	v.	You would not otherwise be entitled to the benefits provided under your Agreement had you not agreed to execute this Release; and 

  

	vi.	Your agreement to the terms set forth above is voluntary. 

  
 3 

 By my signature below I acknowledge and agree to the terms of this Release as of the date
indicated below. 
  

	
	 Ari Bousbib

	
	   

	 Date: _______________

 [Signature Page to Ari Bousbib Release Agreement] 

  
 4Exhibit 10.1

 

COOPERATION AGREEMENT

 

This Cooperation Agreement
(this “Agreement”) is made and entered into as of July 25, 2018, by
and between Iconix Brand Group, Inc., a Delaware corporation (the “Company”),
and Sports Direct International plc, a public limited company organized under the laws of England and Wales (“Investor”)
(each of the Company and Investor, a “Party” to this Agreement, and
collectively, the “Parties”).

 

RECITALS

 

WHEREAS, as of the
date hereof, Investor is deemed to beneficially own shares of the Company’s common stock, $0.001 par value per share (the
 “Company Common Stock”), totaling, in the aggregate, 5,664,115 shares
of the Company Common Stock issued and outstanding on the date hereof;

 

WHEREAS, Investor,
on behalf of itself and its Affiliates (as hereinafter defined), is agreeing to (i) irrevocably withdraw the notice of stockholder
nomination of individuals for election as directors of the Company at the Company’s 2018 annual meeting of stockholders (the
 “2018 Annual Meeting”) submitted to the Company on May 31, 2018 and any related materials or notices submitted
to the Company in connection therewith and (ii) terminate its solicitation of proxies in connection with the 2018 Annual Meeting;

 

WHEREAS, as of the
date hereof, the Company and Investor have determined that it is in their respective best interests to come to an agreement to
modify the composition of the Company’s board of directors (the “Board”)
and as to certain other matters, as provided herein; and

 

WHEREAS, the Company
and the Board intend to work constructively and collaboratively with the Investor Directors (as hereinafter defined) to undertake
an operational review of the Company’s business and strategy in order to improve the Company’s performance.

 

NOW, THEREFORE, in
consideration of the foregoing premises and the mutual covenants and agreements contained herein, and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound hereby,
agree as follows:

 

		1.	Board Matters and Related Agreements.

 

(a)       Initial
Investor Director. Promptly following the execution of this Agreement, the Company hereby agrees to cause the Board and all
applicable committees thereof to take all necessary actions to appoint Justin Barnes, as representative of Investor (the “Initial
Investor Director”), as a director of the Company to serve until the 2018 Annual Meeting and thereafter in accordance
with Section 1(c) hereof. The Board, based on information provided by Investor and the Initial Investor Director, has determined
that the Initial Investor Director would (i) qualify as an “independent director” under the applicable rules of The
Nasdaq Global Market (“Nasdaq”) and the rules and regulations of the
U.S. Securities and Exchange Commission (the “SEC”) and (ii) satisfy
the guidelines and policies with respect to service on the Board applicable to all non-management directors (including the requirements
set forth in clauses (iii)-(iv) of Section 1(i) hereof).

 

(b)       Additional
Investor Director. The Company and the Investor agree that following the execution of this Agreement, James Marcum shall be
designated as the “Additional Investor Director” (and together with
the Initial Investor Director, the “Investor Directors”) to serve until
the 2018 Annual Meeting and thereafter in accordance with Section 1(c) hereof. The Board, based on information provided
by Investor and the Additional Investor Director, has determined that the Additional Investor Director would (i) qualify as an
 “independent director” under the applicable rules of Nasdaq and the rules and regulations of the SEC, (ii) satisfy
the guidelines and policies with respect to service on the Board applicable to all non-management directors (including the requirements
set forth in clauses (iii)-(iv) of Section 1(i) hereof), and (iii) qualify to serve on an audit committee under the applicable
rules of Nasdaq and the rules and regulations of the SEC.

 

     

     

    

  

(c)       2018
and 2019 Annual Meetings. The Board and all applicable committees thereof shall take all necessary actions so that each Investor
Director (or any Investor Replacement Director (as hereinafter defined), if applicable) shall stand for election as directors at
the 2018 Annual Meeting. The Company agrees that its slate of nominees for election as directors of the Company at the 2018 Annual
Meeting shall consist of not more than six (6) director nominees, including the Initial Investor Director (or any Investor Replacement
Director, if applicable), the Additional Investor Director (or any Investor Replacement Director, if applicable), F. Peter Cuneo,
Drew Cohen, Mark Friedman and Sue Gove; provided that, notwithstanding the foregoing, the Company’s slate of nominees
for election as directors of the Company at the 2018 Annual Meeting may consist of seven (7) director nominees if the Company’s
permanent Chief Executive Officer is identified and appointed pursuant to Section 1(i)(ix) prior to the mailing date of the Company’s
proxy statement for the 2018 Annual Meeting. The Company agrees to recommend, support and solicit proxies for the election of the
Initial Investor Director and the Additional Investor Director (or any Investor Replacement Director, if applicable), at the 2018
Annual Meeting in the same manner and to the same extent as for the Company’s other nominees. If any Investor Director is
elected as a director at the 2018 Annual Meeting, such Investor Director shall serve until the Company’s 2019 annual meeting
of stockholders (the “2019 Annual Meeting”), or until his or her earlier
death, resignation, disqualification or removal. The Company shall use its reasonable best efforts to hold the 2018 Annual Meeting
no later than October 1, 2018. The Company shall use its reasonable best efforts to hold the 2019 Annual Meeting prior to May 31,
2019. The Board in its reasonable judgment, after receiving the advice of counsel, may determine to delay the 2019 Annual Meeting
past May 31, 2019 if it reasonably believes that it would be in the best interests of the Company and/or its stockholders to do
so.

 

		(d)	Board Size.

 

(i)       Notwithstanding
anything to the contrary herein and subject in all respects to Section 1(i)(vii) hereof,

 

  (A)
   unless Investor consents in writing to an increase in the size of the Board, the Company agrees that from the date hereof
until the 2018 Annual Meeting, the Board and all applicable committees thereof shall take all necessary actions so that the
size of the Board is no greater than nine (9) directors; and

 

  (B)
   unless Investor consents in writing to an increase in the size of the Board, the Company agrees that following the 2018
Annual Meeting and during the Standstill Period (as hereinafter defined), the Board and all applicable committees thereof
shall take all necessary actions so that the size of the Board is no greater than six (6) directors; provided that,
notwithstanding the foregoing, the Board may be expanded to seven (7) directors to appoint the Company’s permanent
Chief Executive Officer as a director, once identified, pursuant to Section 1(i)(ix).

 

(ii)       During
the Standstill Period, the Company shall from time to time cause incumbent members of the Board (other than the Investor Directors)
to promptly resign from the Board and all applicable committees thereof, and the Board and all applicable committees thereof shall
accept such resignations and take such other actions as may be necessary in order to give effect to Sections 1(a)-1(d) hereof
and the other terms and provisions of this Agreement.

 

    2 

     

    

  

(e)       Committees.
The Company agrees that, concurrent with the appointment of the Initial Investor Director to the Board, the Board and all applicable
committees thereof shall take all necessary actions to appoint the Initial Investor Director to each of the Nominating and Governance
Committee of the Board (the “Nominating Committee”) and the ad hoc
CEO Search Committee of the Board (the “Search Committee”) to serve until the date of the 2019 Annual Meeting
or the Initial Investor Director’s earlier death, resignation or removal. The Company also agrees that, immediately following
the execution of this Agreement, the Board and all applicable committees thereof shall take all necessary actions for the Additional
Investor Director to continue to serve as a member of the Audit Committee of the Board until at least the date of the 2019 Annual
Meeting or the Additional Investor Director’s earlier death, resignation or removal. Substantially concurrently with the
execution of this Agreement, the Company further agrees to establish a steering committee, which shall not be a committee of the
Board (the “Steering Committee”), to undertake an operational review of the Company’s business. The Board
shall cause the Steering Committee to adopt a charter, substantially in the form attached hereto as Exhibit A hereto. The
Steering Committee shall remain in effect during the Standstill Period and, if determined by the Board, thereafter. The initial
members of the Steering Committee shall consist of the Initial Investor Director, the Additional Investor Director, Mr. Friedman,
Ms. Gove, at least one member of management of the Company (which shall be Mr. Cuneo) as well as the new permanent Chief Executive
Officer (when identified and appointed). The Steering Committee shall only have authority to make recommendations to the full Board
regarding actions to be considered in furtherance of the Steering Committee’s purpose. The Board shall have the sole right
to review and approve or reject any recommendations made by the Steering Committee.

 

(f)       SDI
Adviser. The Company hereby agrees that during the Standstill Period, for so long as Investor has aggregate beneficial ownership
(as determined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended, or the rules or regulations
promulgated thereunder (the “Exchange Act”)) of at least four percent
(4.0%) of the then-outstanding Company Common Stock (provided that such percentage shall be adjusted to give effect to any
share issuance or similar Company action that increases the number of outstanding shares of Company Common Stock (other than ordinary
course compensatory equity issuances to management)) (the “Minimum Ownership Threshold”),
Investor shall have the right to designate one (1) individual (who (x) resides in the United States of America and (y) may be affiliated
with Investor as an employee of Investor, any of its Affiliates or otherwise) as a non-voting observer (such individual, the “SDI
Adviser”) to attend any meetings of (1) the Board or committees thereof or (2) the Steering Committee; provided
that such SDI Adviser shall not (i) have the right to vote at any meetings of the Board (or committees thereof) or meetings of
the Steering Committee or (ii) be counted toward determining whether there is quorum for such meetings; provided, further,
that the Company agrees that the SDI Adviser shall not have or be deemed to have, or otherwise be subject to, any duties (fiduciary
or otherwise) to the Company or its Affiliates or any of their stockholders. The Investor shall identify the initial SDI Adviser
designee and each successor SDI Adviser designee, as applicable, by delivering a written notice of designation to the Chairman
of the Board from time to time at its discretion. During the Standstill Period, Investor shall have the right to remove and replace
the SDI Adviser at any time and from time to time. In the event that both of the Investor Directors resign from the Board in accordance
with clause (iii) of Section 1(i) hereof, Investor shall have no further rights under this Section 1(f) and shall
immediately cause its SDI Adviser to resign.

 

    3 

     

    

 

(g)       Replacement
Rights. If either of the Investor Directors (or any Investor Replacement Director, if applicable)
is unable or unwilling to serve as a director for any reason, resigns as a director or is removed as a director prior to the expiration
of the Standstill Period (including, with respect to the Additional Investor Director, a resignation made pursuant to the Additional
Investor Director Resignation under Section 1(i)(iii)), and at such time Investor has aggregate beneficial ownership (as
determined under Rule 13d-3 promulgated under the Exchange Act) of at least the Minimum Ownership Threshold, Investor shall have
the ability to recommend a substitute person(s) reasonably acceptable to the Board (which acceptance shall not be unreasonably
withheld or delayed) (any such replacement nominee shall be referred to as the “Investor Replacement Director”).
Any Investor Replacement Director recommended by Investor shall be required to (i) qualify as an “independent director”
under the applicable rules of Nasdaq and the rules and regulations of the SEC and (ii) satisfy the guidelines and policies with
respect to service on the Board applicable to all non-management directors. The Nominating Committee shall promptly (and in no
case later than ten (10) business days after the Investor submits its recommendation) make its determination and recommendation
regarding whether such person so qualifies as soon as practicable after (i) such nominee has submitted to the Company the documentation
set forth in clause (iv) of Section 1(i) herein, (ii) representatives of the Board have conducted customary interview(s)
of such nominee and (iii) the Nominating Committee has completed its diligence process with regard to such nominee to its reasonable
satisfaction. The Company shall use its reasonable best efforts to conduct any interview(s) and diligence contemplated in this
Section 1(g) as promptly as practicable, but in any case, assuming reasonable availability of the nominee, within five (5)
business days after Investor’s submission of such nominee and such nominee’s submission of the documentation set forth
in clause (iv) of Section 1(i) herein. In the event the Nominating Committee does not accept a substitute person recommended
by Investor as the Investor Replacement Director, Investor shall have the right to recommend additional substitute person(s), whose
appointment shall be subject to the Nominating Committee recommending such person in accordance with the procedures described above
and the Board’s vote to appoint such person in accordance with the procedures described below. Upon the recommendation of
a nominee as the Investor Replacement Director by the Nominating Committee, the Board shall vote on the appointment of such Investor
Replacement Director to the Board as soon as practicable after the Nominating Committee’s recommendation of such Investor
Replacement Director; provided, however, that if the Board does not elect such Investor Replacement Director to the
Board, the Parties shall continue to follow the procedures of this Section 1(g) until an Investor Replacement Director is
elected to the Board. Subject to applicable rules of Nasdaq and the rules and regulations of the SEC, the Board and all applicable
committees thereof shall take all necessary actions to appoint any Investor Replacement Director to any applicable committee of
the Board of which the Initial Investor Director or the Additional Investor Director, as applicable, was a member immediately prior
to such Initial Investor Director’s or such Additional Investor Director’s, as applicable, resignation or removal;
provided that such Investor Replacement Director is qualified to serve on any such committee of the Board. Any Investor
Replacement Director appointed to the Board in accordance with this Section 1(g) will be legally bound by the terms and
conditions applicable to the Initial Investor Director or the Additional Investor Director, as applicable, under this Agreement.
Following the appointment of any Investor Replacement Director to replace either of the Investor Directors in accordance with this
Section 1(g), all reference to the Initial Investor Director or the Additional Investor Director, as applicable, herein
shall be deemed to include any Investor Replacement Director (it being understood
that this sentence shall apply whether or not references to the Initial Investor Director and/or the Additional Investor Director
expressly state that they include any Investor Replacement Director). If at any time Investor’s aggregate beneficial ownership
(as determined under Rule 13d-3 promulgated under the Exchange Act) of the Company Common Stock decreases to less than the Minimum
Ownership Threshold, the right of Investor pursuant to this Section 1(g) to participate in the recommendation of an Investor
Replacement Director to fill the vacancy caused by the resignation or removal of either of the Investor Directors or any Investor
Replacement Director shall automatically terminate. Prior to the appointment of any Investor Replacement Director to the Board,
(i) Investor will deliver to the Company an irrevocable resignation letter addressed to the Company pursuant to which the Investor
Replacement Director shall offer to resign from the Board and all applicable committees thereof if, at any time during the Standstill
Period, Investor’s aggregate beneficial ownership (as determined under Rule 13d-3 promulgated under the Exchange Act), of
the Company Common Stock decreases to less than the Minimum Ownership Threshold, such irrevocable resignation not to be effective
until the Board shall have accepted such resignation, which acceptance shall be made within the sole and absolute discretion of
the Board, and (ii) the Investor Replacement Director will submit to the Company the information, documentation and acknowledgements
set forth in clause (iv) of Section 1(i) hereof.

 

    4 

     

    

 

(h)       Withdrawal
of Nominations, Proxy Solicitation and Other Demands. Investor, on behalf of itself and its Affiliates, hereby (i) irrevocably
withdraws the notice of stockholder nomination of individuals for election as directors of the Company at the 2018 Annual Meeting
submitted to the Company on May 31, 2018; (ii) agrees not to submit any notice of nomination of individuals for election as directors
of the Company at the 2018 Annual Meeting; (iii) agrees to terminate immediately its solicitation of proxies in connection with
the 2018 Annual Meeting; and (iv) irrevocably withdraws any related materials or notices submitted to the Company in connection
therewith.

 

(i)       Additional
Agreements.

 

(i)       Each
of the Company and Investor agrees that it will cause its controlled Affiliates and Associates to comply with the terms of this
Agreement and shall be responsible for any breach of this Agreement by any such controlled Affiliate or Associate. As used in this
Agreement, the terms “Affiliate” and “Associate” shall have the respective meanings set forth in Rule 12b-2
promulgated by the SEC under the Exchange Act, and shall include all persons or entities that at any time during the term of this
Agreement become Affiliates or Associates of any person or entity referred to in this Agreement.

 

(ii)       Investor
agrees that it will (A) continue to have the sole right to vote 5,664,115 shares of the Company Common Stock through the date of
the 2018 Annual Meeting, (B) be present for quorum purposes at the 2018 Annual Meeting, (C) vote or cause to be voted all shares
of the Company Common Stock beneficially owned, or deemed beneficially owned (as determined under Rule 13d-3 promulgated under
the Exchange Act), by Investor in favor of (x) the slate of directors recommended by the Board at the 2018 Annual Meeting (which
will be made in accordance with the terms hereof) and (y) the Company’s reverse stock split proposal and (D) vote in accordance
with the Board’s recommendation with respect to any other proposal presented at the 2018 Annual Meeting, unless Institutional
Shareholder Services Inc. (“ISS”) issues a recommendation against the Board’s position, in which case,
Investor shall have the right to vote in accordance with such ISS recommendation; provided that the obligations contained
in clause (D) above shall not apply to any matters to be voted on at the 2018 Annual Meeting or corresponding Board recommendations
that have not been accurately described in writing to Investor prior to the date hereof.

 

(iii)       Prior
to the date hereof, the Investor Directors have each delivered to the Company an executed irrevocable resignation letter as a director
pursuant to which each of the Investor Directors agrees to resign from the Board and all applicable committees thereof if (x) at
any time Investor’s aggregate beneficial ownership (as determined under Rule 13d-3 promulgated under the Exchange Act) of
the Company Common Stock decreases to less than the Minimum Ownership Threshold or (y) Investor or any of its Affiliates or Associates
nominates one or more director candidates for election to the Board at the 2019 Annual Meeting pursuant to the By-Laws. Each of
the Investor Director’s irrevocable resignation made pursuant to the forgoing sentence shall not be effective until the Board
shall have accepted such resignation, which acceptance shall be made within the sole and absolute discretion of the Board. Prior
to the date hereof, the Additional Investor Director has delivered to the Company and the Investor an executed irrevocable resignation
letter as a director (the “Additional Investor Director Resignation”), pursuant to which the Additional Investor
Director agrees to resign from the Board and all applicable committees thereof immediately upon written notice provided by the
Investor (in its sole discretion) to the Additional Investor Director and the Board stating that the Investor desires that the
Additional Investor Director resign from the Board. The Company and the Board shall take all necessary actions to accept and give
full effect to the Additional Investor Director Resignation upon receiving the written notice from the Investor referred to in
the forgoing sentence.

 

    5 

     

    

 

(iv)       Prior
to the date hereof, the Initial Investor Director has (i) delivered to the Company (A) a fully completed copy of the Company’s
standard director & officer questionnaire and other reasonable and customary director onboarding documentation required by
the Company’s written policies and procedures of non-management directors in connection with the appointment or election
of new Board members; (B) the information required pursuant to Section 5(a)(2)(a) and (b) of Article II of the Company’s
Restated and Amended By-Laws (the “By-Laws”), except for (x) the information
that is provided hereunder, (y) the information required under Section 5(a)(2)(b) of Article II of the By-Laws that was previously
provided to the Company in connection with the 2018 Annual Meeting and remains unchanged as of the date hereof and (z) the information
required by Section 5(a)(2)(a)(vi) of Article II of the By-Laws; and (C) a written acknowledgment in substantially the form entered
into by the other directors of the Company that the Initial Investor Director agrees to be bound by all current policies, codes
and guidelines applicable to directors of the Company, including, without limitation, the Company’s trading policy, code
of conduct and ethics for directors, corporate governance guidelines and any related person transaction policy (the “Company
Policies”); and (ii) telephonically met with members of the Nominating Committee, the Executive Chairman of the
Board and certain other members of the Board, if any. The Company agrees that each Investor Director shall (i) be indemnified by
the Company in the same manner as all other non-management directors of the Company and (ii) receive the benefit of customary directors’
and officers’ liability insurance coverage in accordance with the terms of any such insurance policy.

 

(v)       If,
in the exercise of its fiduciary duties and after consulting with its legal counsel, the Board determines in good faith that an
Investor Director or the SDI Adviser has a conflict of interest with respect to any SDI Matter, then the Board may, by majority
vote of the members of the Board (but excluding the Investor Directors), recuse such conflicted Investor Director or SDI Adviser,
as applicable, from the portion of any Board or committee meeting (including the Steering Committee) at which the Board or any
such committee is discussing such SDI Matter. For purposes hereof, the term “SDI Matter” means any matter being
considered by the Board or any committee relating to this Agreement, Investor or any Affiliate of Investor, it being understood
that no Investor Director shall be recused from matters not relating to this Agreement or Investor merely because such Investor
Director may be deemed to be an Affiliate of Investor. Notwithstanding anything in this Section 1(i)(v) and without limiting the
foregoing, the Initial Investor Director shall not be prohibited from privately (without any public disclosure) making any proposals
to the Board for its consideration, including proposals with respect to Investor and its Affiliates, and explaining the rationale
for any such proposal prior to his recusal.

 

(vi)       The
Company agrees that each of the Investor Directors (and any Investor Replacement Director, if applicable) shall receive the same
annual compensation as other non-employee directors of the Company and shall be entitled to reimbursement for each of the Investor
Director’s documented and reasonable out-of-pocket expenses on the same basis as all other directors of the Company in their
capacity as such. The Company also agrees that the SDI Adviser shall be compensated with a quarterly fee for his or her service
in an amount equal to twenty thousand dollars ($20,000) per quarter, to be paid by the Company to the SDI Adviser within thirty
(30) days following the last day of each calendar quarter. The SDI Adviser shall receive expense reimbursement from the Company
for his or her documented and reasonable out-of-pocket expenses to attend any meetings of the Board, any committee of the Board
and the Steering Committee; provided that any such expense reimbursement shall be consistent with the Company’s expense
reimbursement policy applicable to all non-management directors as may be in effect from time to time.

 

    6 

     

    

 

(vii)       During
the Standstill Period, unless required by law or its organizational documents, the Board and the Company shall not call or support
any special meetings of stockholders of the Company for the purpose of removing either of the Investor Directors from the Board,
or take any action which would have the effect of curtailing the scope or term of office of either of the Investor Directors. The
Company and the Board will recommend against any proposal or consent solicitation that might be brought to remove or curtail the
scope or term of either of the Investor Directors, and the Company will use its reasonable best efforts to solicit proxies against
any such action. During the Standstill Period, the Company also agrees that, (x) except in the case of the required recusal of
the Investor Directors (and any Investor Replacement Director, if applicable) as contemplated by Section 1(i)(v) hereof,
the Company shall cause the Board not to utilize committees of the Board for the purpose of discriminating against the Investor
Directors in order to limit their participation in substantive deliberations of the Board, (y) the Company will not adopt or enter
into any stockholder rights plan or similar agreement or arrangement that would prohibit, impair or frustrate the ability of Investor
to acquire beneficial ownership of the Company Common Stock to the extent permitted by Section 2(a) hereof, and (z) the
organizational documents of the Company and the guidelines and policies with respect to service on the Board applicable to all
non-management directors shall not be amended, supplemented or replaced in any manner that would discriminate against the Investor
Directors or in any manner that would be inconsistent with the terms of this Agreement.

 

(viii)       During
the Standstill Period, neither the Company nor any of its Affiliates or Associates under its control or direction will, and the
Company will cause each of its Affiliates and Associates under its control not to, directly or indirectly, in any manner, alone
or in concert with others commence, institute, solicit, encourage, support or join, as a party, any litigation, arbitration or
other proceeding (including a derivative action) against the Investor Directors, the SDI Adviser, Investor, any of the Investor’s
Affiliates or Associates under its control or any of their respective current or former directors or officers, including any action
challenging the validity or enforceability of this Section 1(i)(viii) or this Agreement, other than (A) litigation by the
Company to enforce the provisions of this Agreement; (B) counterclaims with respect to any proceeding initiated by, or on behalf
of, Investor or its Affiliates or Associates against the Company, its Affiliates or Associates; and (C) bringing commercial disputes
that do not relate to the subject matter hereof; provided that the foregoing shall also not prevent the Company from responding
to, or complying with, a validly issued legal process that the Company did not initiate, encourage, aid or abet.

 

(ix)       In
connection with the Board’s identification and appointment of a permanent Chief Executive Officer of the Company, the Company
agrees that (A) the Initial Investor Director shall have a reasonable opportunity to participate as a member of the Search Committee
and to interview (which may be telephonically) any candidate being seriously considered by the Board for appointment as the Company’s
permanent Chief Executive Officer, (B) the Search Committee will not make a determination or recommendation to the Board with respect
to the appointment of the Company’s permanent Chief Executive Officer and the Company will not take any action or
enter into any agreement to appoint the Company’s permanent Chief Executive Officer prior to the date that is the later of
sixty (60) days from the date hereof and five (5) calendar days after the 2018 Annual Meeting, unless the Search Committee makes
a unanimous recommendation to the Board regarding appointment of the Company’s permanent Chief Executive Officer prior to
such date, and (C) the Board will consider in good faith the views of the Initial Investor Director and the Additional Investor
Director regarding the skill sets and qualifications required of the Company’s permanent Chief Executive Officer.

 

    7 

     

    

 

		2.	Standstill Provisions.

 

(a)       The
standstill period (the “Standstill Period”) begins on the date of this
Agreement and shall extend until the earlier of (v) the date that is thirty (30) days prior to the deadline for the submission
of stockholder nominations for directors for the 2019 Annual Meeting pursuant to the By-Laws, (w) the date that is thirteen (13)
months after the date of the 2018 Annual Meeting, (x) the date of any breach by the Company in any material respect of its obligations
under this Agreement (but subject to a ten (10) day cure period), and (y) upon written notice from Investor to the Company at any
time following the announcement by the Company of a definitive agreement (or the intent to enter or seek to enter into a definitive
agreement) with respect to any Extraordinary Transaction (as hereinafter defined); provided, however, that, notwithstanding
anything herein to the contrary, if the Standstill Period terminates pursuant to clause 2(a)(x), all of the Company’s and
the Board’s obligations under this Agreement (including, without limitation, all obligations of the Company and the Board
that are expressly limited to the term of the Standstill Period) shall continue to survive and remain in full force and effect
until the Standstill Period would otherwise terminate pursuant to clauses 2(a)(v), (w) or (y) (the “Company’s Surviving
Obligations”). Investor agrees that during the Standstill Period, neither Investor nor any of its Affiliates or Associates
under its control or direction will, and Investor will cause each of its Affiliates and Associates under its control not to, directly
or indirectly, in any manner, alone or in concert with others:

 

(i)       acquire,
offer, seek or agree to acquire, by purchase or otherwise, or direct others in the acquisition of, any securities issued by the
Company or securities convertible into or exchangeable for the Company Common Stock or assets of the Company, or rights or options
to acquire any securities issued by the Company or securities convertible into or exchangeable for the Company Common Stock or
assets of the Company, or engage in any swap or hedging transactions or other derivative agreements of any nature with respect
to securities issued by the Company or securities convertible into or exchangeable for the Company Common Stock that are settled
by delivery of the Company Common Stock or assets of the Company, in the case of each of the foregoing, only if such action would
result in Investor, together with its Affiliates and Associates, having an aggregate beneficial ownership (as determined under
Rule 13d-3 promulgated under the Exchange Act but treating all shares underlying options or synthetic derivatives as outstanding
whether or not then exercisable) of fifteen percent (15.0%) or more of the then-outstanding Company Common Stock immediately following
the consummation of such transaction; provided that nothing herein will require Company Common Stock to be sold to the extent
that Investor exceeds the ownership limit under this clause (a)(i) as the result of a share repurchase or similar Company action
that reduces the number of outstanding shares of the Company Common Stock;

 

(ii)       engage
in any short sale or purchase of any derivative security that derives any significant part of its value from a decline in the market
price or value of any securities of the Company, or enter into any hedging transaction with similar effect;

 

(iii)       publicly
propose or seek to effect (a) any tender or exchange offer for the Company’s securities or any merger, consolidation, business
combination, recapitalization, restructuring, extraordinary dividend, significant share repurchase, issuance of fifteen percent
(15%) or more of the Company’s then-outstanding equity or similar transactions involving the Company (each, an “Extraordinary
Transaction”) or (b) any acquisition, sale or disposition of a business or assets representing either (x) ten percent
(10%) or more of the fair market value of assets of the Company or of the market capitalization of the Company or (y) twenty five
percent (25%) or more of the Company’s revenues for the most recent twelve (12) month period; provided that if the
Company or a third party has publicly announced any transaction described in this clause (iii) or if the Company or any third party
has publicly announced an intention to engage in or seek such a transaction, then none of the following restrictions shall apply:
(x) the restrictions contained in this clause (iii), (y) the restrictions contained in Section 2(a)(i), and (z) any other restrictions
contained in this Agreement that would prevent or otherwise conflict with the ability of the Investor (or any of its Affiliates
or Associates under its control or direction) to publicly announce, engage in or seek to engage in any transaction described in
this clause (iii); provided, however, that, for the avoidance of doubt, the foregoing shall not prevent the Company
from adopting a stockholder rights plan or similar agreement that would result in a “flip in” event in the event Investor
acquires fifteen percent (15%) or more of the Company Common Stock; provided, further, that this restriction in this
clause (iii) shall not prohibit the Investor Directors from privately (without any public disclosure) advocating for such matters
with the Board;

 

    8 

     

    

 

(iv)       make
a stockholder proposal or seek any form of proxy with respect to the removal, election or appointment of any person to, or representation
of any person on, the Board, or becoming a participant with a third party in any solicitation of any such proxies (including a
 “withhold” or similar campaign) or making statements regarding how Investor intends to vote with respect to a proposal
being voted on by stockholders, or instructing or recommending to other stockholders how to vote with respect to a proposal being
voted on by stockholders;

 

(v)       deposit
Company Common Stock in a voting trust or similar arrangement with any person other than Investor’s Affiliates;

 

(vi)       except
as specifically contemplated by this Agreement, publicly seek additional representation on the Board or the removal of any member
of the Board or encourage any person to submit nominees in furtherance of a contested election;

 

(vii)       make
any public disclosure regarding any plan or proposal with respect to the Board, the Company, its management or policies, any of
its securities or assets or any of its businesses or strategy that, in each case, would be inconsistent with the other provisions
of this Section 2 or the other terms of this Agreement;

 

(viii)       make
any request for a stockholder list of materials or any other books and records of the Company under Section 220 of the Delaware
General Corporation Law (the “DGCL”) or otherwise;

 

(ix)       make
any public request or submit any public proposal to amend or waive any term of this Agreement (including the provisions of this
Section 2) or take any action that could reasonably lead to public disclosure of such a request or proposal by any Party;

 

(x)       commence,
institute, solicit, encourage, support or join, as a party, any litigation, arbitration or other proceeding (including a derivative
action) against the Company or any of its current or former directors or officers, including any action challenging the validity
or enforceability of this Section 2 or this Agreement, other than (A) litigation by Investor to enforce the provisions of
this Agreement; (B) counterclaims with respect to any proceeding initiated by, or on behalf of, the Company or its Affiliates against
Investor, its Affiliates or Associates; (C) the exercise of statutory appraisal, dissenters or similar rights under the DGCL; and
(D) bringing commercial disputes that do not relate to the subject matter hereof; provided that the foregoing shall also
not prevent Investor from responding to, or complying with, a validly issued legal process that Investor did not initiate, encourage,
aid or abet; or

 

    9 

     

    

 

(xi)       enter
into any negotiations, arrangements, discussions, agreements or understandings with others (whether written or oral) to take any
action with respect to any of the foregoing, or knowingly advise, facilitate, finance (through equity, debt or otherwise), assist,
solicit, encourage or seek to persuade any other person or entity to take any action inconsistent with any of the foregoing.

 

(b)       Subject
to complying with its obligations under Sections 2(a), 11 and 12 hereof, Investor may engage in any private
discussions with the Company’s senior management or any member of the Board so long as such private communications would
not be reasonably determined to trigger public disclosure obligations for any such party.

 

(c)       The
restrictions in this Section 2 shall not prevent Investor or any of its Affiliates from making any factual statement as
required by applicable legal process, subpoena, or legal requirement from any governmental authority with competent jurisdiction
over the party from whom information is sought (so long as such request did not arise as a result of acts by Investor or any of
its Affiliates in violation of the terms of this Agreement).

 

(d)       Nothing
in this Section 2 shall be deemed to limit the exercise in good faith by an Investor Director of his or her fiduciary duties
solely in his or her capacity as a director of the Company.

 

		3.	Representations and Warranties of the Company.

 

The Company represents
and warrants to Investor that (a) the Company has the corporate power and authority to execute this Agreement and to bind the Company
thereto, (b) this Agreement has been duly and validly authorized, executed and delivered by the Company, constitutes a valid and
binding obligation and agreement of the Company, and is enforceable against the Company in accordance with its terms, except as
enforcement thereof may be limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance or similar
laws generally affecting the rights of creditors and subject to general equity principles and (c) the execution, delivery and performance
of this Agreement by the Company does not and will not (i) violate or conflict with any law, rule, regulation, order, judgment
or decree applicable to the Company, or (ii) result in any breach or violation of or constitute a default (or an event which with
notice or lapse of time or both could constitute such a breach, violation or default) under or pursuant to, or result in the loss
of a material benefit under, or give any right of termination, amendment, acceleration or cancellation of, any organizational document,
agreement, contract, commitment, understanding or arrangement to which the Company is a party or by which it is bound.

 

    10 

     

    

 

		4.	Representations and Warranties of Investor.

 

Investor represents and warrants to the Company that (a) the
authorized signatory of Investor set forth on the signature page hereto has the power and authority to execute this Agreement and
any other documents or agreements to be entered into in connection with this Agreement and to bind Investor thereto; (b) this Agreement
has been duly authorized, executed and delivered by Investor, and is a valid and binding obligation of Investor, enforceable against
Investor in accordance with its terms, except as enforcement thereof may be limited by applicable bankruptcy, insolvency, reorganization,
moratorium, fraudulent conveyance or similar laws generally affecting the rights of creditors and subject to general equity principles;
(c) the execution of this Agreement, the consummation of any of the transactions contemplated hereby, and the fulfillment of the
terms hereof, in each case in accordance with the terms hereof, will not conflict with, or result in a breach or violation of the
organizational documents of Investor as currently in effect; (d) the execution, delivery and performance of this Agreement by Investor
does not and will not (i) violate or conflict with any law, rule, regulation, order, judgment or decree applicable to Investor,
or (ii) result in any breach or violation of or constitute a default (or an event which with notice or lapse of time or both could
constitute such a breach, violation or default) under or pursuant to, or result in the loss of a material benefit under, or give
any right of termination, amendment, acceleration or cancellation of, any organizational document, agreement, contract, commitment,
understanding or arrangement to which Investor is a party or by which it is bound; (e) as of the date hereof, Investor is deemed
to beneficially own (as determined under Rule 13d-3 promulgated under the Exchange Act), in the aggregate, 5,664,115 shares of
the Company Common Stock and will be entitled to vote all of such shares of the Company Common Stock at the 2018 Annual Meeting;
(f) as of the date hereof, Investor does not currently have, and does not currently have any right to acquire or any interest in
any other securities of the Company (or any rights, options or other securities convertible into or exercisable or exchangeable
(whether or not convertible, exercisable or exchangeable immediately or only after the passage of time or the occurrence of a specified
event) for such securities or any obligations measured by the price or value of any securities of the Company or any of its Affiliates,
including any swaps or hedging transactions or other derivative arrangements designed to produce economic benefits and risks that
correspond to the ownership of Company Common Stock, whether or not any of the foregoing would give rise to beneficial ownership
(as determined under Rule 13d-3 promulgated under the Exchange Act), and whether or not to be settled by delivery of Company Common
Stock, payment of cash or by other consideration, and without regard to any short position under any such contract or arrangement);
(g) Investor will not compensate or agree to compensate (including with cash, securities or any rights or options convertible into
or exercisable for or exchangeable into securities or any profit sharing agreement or arrangement) the Investor Directors for their
services as directors of the Company or the SDI Adviser for his or her services with respect to the Board as the SDI Adviser to
the extent such compensation paid to the Investors Directors or the SDI Adviser is directly related to (i) the financial performance
of the Company or the Company’s securities or (ii) the Company or its Affiliates entering into any transaction; provided,
however, that Investor may pay or provide discretionary compensation to any of the Investor Directors based on the performance
of the Company or its stock price if such discretionary compensation is disclosed in writing in advance to the Board; provided,
further that nothing herein shall restrict or require disclosure of any compensation paid to the SDI Adviser (or the SDI Adviser’s
Affiliates, employers or clients) for the rendering of legal services to Investor, the Investor Directors or any of their respective
Affiliates, including with respect to the Company and/or the Board; and (h) (i) as of the date hereof, Investor, the Initial
Investor Director and any of their respective Affiliates are not, directly or indirectly, working, coordinating or collaborating
with Neil Cole on any matter related to the Company or its Affiliates and (ii) during the Standstill Period, senior management
of Investor, the Initial Investor Director, any other Investor Director (or any Investor Replacement Director, if applicable) that
is a Representative of or employed by Investor, the SDI Adviser and any of their respective Affiliates will not, directly or indirectly,
work, coordinate or collaborate with Neil Cole on any matter related to the Company or its Affiliates (any such action, a “NC
Action”); provided, however, that the foregoing shall not prohibit (v) any party from accepting a call
or other communication from Neil Cole, including receiving any proposal from Mr. Cole regarding the Company or its Affiliates,
provided, further that before taking any action in furtherance of any NC Action, such party must receive the advance approval of
the Board, (w) any party from merely holding discussions with Neil Cole if such discussions do not involve a NC Action, (x) any
Investor Director (or any Investor Replacement Director, if applicable), in his or her capacity as such, from participating in
or discussing any NC Action that the Company or the Board is taking or discussing, (y) any party from taking any NC Action that
is approved in advance by a majority of the members of the Board, or (z) any Investor Director (or any Investor Replacement Director,
if applicable) from taking any NC Action that it believes in good faith is required in order to comply with his or her fiduciary
duties to the Company and its stockholders pursuant to applicable laws; provided that written notice is provided to the
Board in advance of taking any such NC Action (which written notice shall include a reasonably detailed description of why such
Investor Director believes in good faith that his or her fiduciary duties require such NC Action).

 

    11 

     

    

 

		5.	Termination.

 

This Agreement shall
remain in full force and effect until the earliest of:

 

(a)       the
expiration of the Standstill Period; or

 

(b)       such
other date established by mutual written agreement of the Parties;

 

provided that such termination shall
not relieve (i) any Party, the SDI Adviser or any Investor Director from their respective obligations under each of Section
12 hereof and the Confidentiality Agreement (as hereinafter defined), which obligations shall survive in accordance with their
terms, or (ii) the survival of the Company’s Surviving Obligations pursuant to Section 2(a), if applicable.

 

		6.	Specific Performance.

 

Each of Investor, on
the one hand, and the Company, on the other hand, acknowledges and agrees that irreparable injury to the other Party would occur
in the event any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise
breached and that such injury would not be adequately compensable by the remedies available at law (including the payment of money
damages). It is accordingly agreed that Investor, on the one hand, and the Company, on the other hand (the “Moving
Party”), shall each be entitled to specific enforcement of, and injunctive relief to prevent any violation of,
the terms hereof (without the requirement of posting a bond), and the other Party will not take action, directly or indirectly,
in opposition to the Moving Party seeking such relief on the grounds that any other remedy or relief is available at law or in
equity. This Section 6 is not the exclusive remedy for any violation of this Agreement.

 

		7.	Severability.

 

If any term, provision,
covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, void or unenforceable, the
remainder of the terms, provisions, covenants and restrictions of this Agreement shall remain in full force and effect and shall
in no way be affected, impaired or invalidated. The Parties agree to use their commercially reasonable best efforts to agree upon
and substitute a valid and enforceable term, provision, covenant or restriction for any of such that is held invalid, void or enforceable
by a court of competent jurisdiction.

 

    12 

     

    

 

		8.	Notices.

 

Any notices, consents,
determinations, waivers or other communications required or permitted to be given under the terms of this Agreement must be in
writing and will be deemed to have been delivered: (i) upon receipt, when delivered personally; (ii) upon receipt, when sent by
facsimile (provided confirmation of transmission is mechanically or electronically generated and kept on file by the sending Party);
(iii) upon confirmation of receipt, when sent by email (provided such confirmation is not automatically generated); or (iv) one
(1) business day after deposit with a nationally recognized overnight delivery service, in each case properly addressed to the
Party to receive the same. The addresses and facsimile numbers for such communications shall be:

 

	If to the Company:	
        Iconix Brand Group, Inc.

        1450 Broadway, Third Floor

        New York, New York 10018

        

        

        

        

	 	Attention:	Jason Schaefer
	 	Telephone:	(212) 730-0030
	 	Facsimile:	(212) 391-2057
	 	Email:	JSchaefer@iconixbrand.com
	 	 
	With a copy (which shall not constitute notice) to:	
        Skadden, Arps, Slate, Meagher & Flom LLP

        4 Times Square

        New York, NY 10036

        

        

        

        

	 	Attention:	 Richard J. Grossman
	 	Telephone:	(212) 735-2116
	 	Facsimile:	(917) 777-2116
	 	Email:	Richard.Grossman@skadden.com
	 	 
	If to Investor:	
        Sports Direct International plc

        Unit A, Brook Park East

        Shirebrook

        NG20 8RY

        United Kingdom

        

        

        

	 	Attention:	Cameron Olsen
	 	Telephone:	+(44) (845) 1299-289
	 	Email:	colsen@ibml.co.uk
	 	 
	With a copy (which shall not constitute notice) to:	
        Reed Smith LLP

        599 Lexington Avenue, Floor 22

        New York, New York 10222

        

        

        

        

	 	Attention:	David M. Grimes
	 	Telephone:	(212) 549-0240
	 	Facsimile:	(212) 521-5400
	 	Email:	DGrimes@reedsmith.com

 

		9.	Applicable Law.

 

This Agreement shall
be governed by and construed and enforced in accordance with the laws of the State of Delaware without reference to the conflict
of laws principles thereof. Each of the Parties irrevocably agrees that any legal action or proceeding with respect to this Agreement
and the rights and obligations arising hereunder, or for recognition and enforcement of any judgment in respect of this Agreement
and the rights and obligations arising hereunder brought by the other Party or its successors or assigns, shall be brought and
determined exclusively in the federal or state courts located in Wilmington, Delaware. Each of the Parties hereby irrevocably submits
with regard to any such action or proceeding for itself and in respect of its property, generally and unconditionally, to the personal
jurisdiction of the aforesaid courts and agrees that it will not bring any action relating to this Agreement in any court other
than the aforesaid courts. Each of the Parties further agrees that service of any process, summons, notice or document by registered
mail to the respective addresses set forth in Section 8 hereof shall be effective service of process for any action relating
to this Agreement brought against any such Party in any such court. Each of the Parties hereby irrevocably waives, and agrees not
to assert in any action or proceeding with respect to this Agreement, (i) any claim that it is not personally subject to the jurisdiction
of the above-named courts for any reason, (ii) any claim that it or its property is exempt or immune from jurisdiction of any such
court or from any legal process commenced in such courts (whether through service of notice, attachment prior to judgment, attachment
in aid of execution of judgment, execution of judgment or otherwise) and (iii) to the fullest extent permitted by applicable legal
requirements, any claim that (A) the suit, action or proceeding in such court is brought in an inconvenient forum, (B) the venue
of such suit, action or proceeding is improper or (C) this Agreement, or the subject matter hereof, may not be enforced in or by
such courts. EACH OF THE PARTIES WAIVES ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY CLAIM BASED UPON, ARISING OUT
OF OR IN CONNECTION WITH, THIS AGREEMENT.

 

    13 

     

    

 

		10.	Counterparts.

 

This Agreement may
be executed in two or more counterparts, each of which shall be considered one and the same agreement and shall become effective
when counterparts have been signed by each of the Parties and delivered to the other Party (including by means of electronic delivery
or facsimile). For the avoidance of doubt, neither Party shall be bound by any contractual obligation to the other Party (including
by means of any oral agreement) until all counterparts to this Agreement have been duly executed by each of the Parties and delivered
to the other Party (including by means of electronic delivery).

 

		11.	Mutual Non-Disparagement.

 

Subject to applicable
law, (including the making of any statement by either Party or their Representatives (as defined below) as required by applicable
subpoena, legal process, other legal requirement, the rules of any securities exchange or the duties applicable to a director),
each of the Parties covenants and agrees that, during the Standstill Period, neither Party nor any of its respective agents, subsidiaries,
affiliates, successors, assigns, principals, partners, members, general partners, officers, key employees or directors (collectively,
 “Representatives”), shall in any way publicly criticize, disparage, call into disrepute, or otherwise defame
or slander the other Party or such other Party’s subsidiaries, affiliates, successors, assigns, officers (including any current
officer of a Party or a Parties’ subsidiaries who no longer serves in such capacity following the execution of this Agreement),
directors (including any current director of a Party or a Parties’ subsidiaries who no longer serves in such capacity following
the execution of this Agreement), employees, stockholders (solely in their capacity as stockholders of the applicable Party), agents,
attorneys or representatives, or any of their businesses, products or services, in any manner that would reasonably be expected
to damage the business, or reputation of the other Party or of its subsidiaries, affiliates, successors, assigns, officers (or
former officers), directors (or former directors), employees, stockholders (solely in their capacity as stockholders of the applicable
Party), agents, attorneys or representatives; provided that neither Party shall be deemed in breach of this Section 11
by virtue of a private, informal remark that is not part of any coordinated communication or campaign and is not intended or designed
to circumvent, directly or indirectly, the restrictions contemplated by this Agreement. In addition to other remedies available
in connection with any breach of this Agreement, nothing shall prevent either Party or its Representatives from responding without
restriction to the other Party’s breach of this Section 11. Notwithstanding anything to the contrary, nothing herein
shall prevent Investor or its Representatives from publicly stating its opinion (which may not contain ad hominem attacks) or making
any objective factual statement regarding any Extraordinary Transaction or any liquidation, dissolution, material license or joint
venture (or material amendment or modification to an existing license or joint venture), or acquisition, sale or disposition of
a business or assets representing either (i) ten percent (10%) or more of the fair market value of assets of the Company or of
the market capitalization of the Company or (ii) twenty five percent (25%) or more of the Company’s revenues for the most
recent twelve (12) month period, or other similar material transaction not in the ordinary course of business between the Company
or any of its subsidiaries and a third party (including, but not limited to, any matter that requires the vote of the Company’s
stockholders, but excluding matters relating to individual personnel decisions by the Company) which is publicly proposed or announced
by the Company or any third party, and nothing herein shall prevent the Company or its Representatives from responding to such
statements.

 

    14 

     

    

 

		12.	Confidentiality.

 

(a)       The
Company hereby agrees that, for as long at least one of the Applicable Investor Directors (as hereinafter defined) is a member
of the Board, any Applicable Investor Director and the SDI Adviser may share non-public information entrusted to or obtained by
such Applicable Investor Director or the SDI Adviser, as applicable, by reason of his or her position as a director or non-voting
observer of the Company (collectively and individually, the “Confidential Information”)
with Investor; provided any such disclosure of the Confidential Information is in accordance with all terms and obligations
of a customary confidentiality agreement, in substantially the form attached hereto as Exhibit B (the “Confidentiality
Agreement”), to be entered into by and between Investor and the Company, which Confidentiality Agreement shall
be entered into as soon as practicable following the date hereof; provided that prior to the SDI Adviser being appointed
pursuant to Section 1(f) hereof, the SDI Adviser shall either become a party to the Confidentiality Agreement or enter into
a customary confidentiality agreement with the Company. The Confidentiality Agreement shall provide, among other things, that (i)
Investor will (x) maintain the strict confidentiality of any Confidential Information received from any Applicable Investor Director
or the SDI Adviser, as applicable, (y) abstain from trading in securities of the Company in violation of applicable law while in
possession of any such Confidential Information and (z) instruct the SDI Adviser to abstain from trading in any securities of the
Company (including any swap or hedging transactions or other derivative agreements of any nature with respect to securities issued
by the Company or securities convertible into or exchangeable for the Company Common Stock (or rights decoupled from the underlying
securities)) for the time periods during which the Investor Directors are prohibited from such trading pursuant to the Company’s
trading policy; and (ii) Investor and the SDI Adviser will only be permitted to trade in the Company’s securities (subject
to applicable law) (1) during any open window periods when members of the Board are permitted to do so and (2) from and any time
after the opening of the first open window period following the date on which all of the Applicable Investor Directors cease to
serve on the Board; provided that the Company will notify the Investor in advance of any such open window trading periods.
 “Applicable Investor Directors” means, collectively, (i) the Initial Investor Director; (ii) each of the Investor
Replacement Directors that replace the Initial Investor Director, if applicable; and (iii) each of the Investor Replacement Directors
that replace the initial Additional Investor Director, if applicable.

 

(b)       The
Confidentiality Agreement shall further provide that any confidentiality obligations pursuant to the Confidentiality Agreement
shall expire eighteen (18) months after the date on which all of the Applicable Investor Directors cease to serve as directors
of the Company; provided that Investor shall maintain in accordance with the confidentiality obligations set forth therein
any Confidential Information constituting trade secrets for such longer time as such information constitutes a trade secret of
the Company as defined under 18 U.S.C. § 1839(3).

 

		13.	Public Announcements.

 

Promptly following
the execution of this Agreement, the Company and Investor shall announce this Agreement by means of a joint press release, in substantially
the form attached hereto as Exhibit C (the “Press Release”).
During the Standstill Period, neither the Company nor Investor shall make or cause to be made any public announcement or statement
with respect to the subject of this Agreement that is inconsistent with or contrary to the statements made in the Press Release,
except as required by law or the rules of any stock exchange or with the prior written consent of the other Party. The Company
acknowledges that Investor may file this Agreement (i) as an exhibit to its Schedule 13D/A and (ii) pursuant to any securities
and/or exchange rules and regulations that are applicable to Investor. The Company shall be given a reasonable opportunity to review
and comment on any Schedule 13D/A filing made by Investor with respect to this Agreement prior to the filing with the SEC, and
Investor shall give reasonable consideration in good faith to any reasonable comments of the Company. Investor acknowledges and
agrees that the Company may file this Agreement and file or furnish the Press Release with the SEC as exhibits to a Current Report
on Form 8-K and other filings with the SEC. Investor shall be given a reasonable opportunity to review and comment on the Form
8-K made by the Company with respect to this Agreement prior to the filing with the SEC, and the Company shall give reasonable
consideration in good faith to any reasonable comments of Investor.

 

    15 

     

    

  

		14.	Expense Reimbursement.

 

Within three (3) business
days of the execution and delivery of this Agreement, the Company shall reimburse Investor for all reasonable and documented out-of-pocket
fees and expenses (including legal fees) incurred by Investor in connection with its director nominations, the 2018 Annual Meeting,
the negotiation and execution of this Agreement, analysis of the corporate governance, debt, and executive compensation of the
Company, and all related activities and matters; provided that such reimbursement shall not exceed $475,000 in the aggregate.

 

		15.	Conflicts Waiver.

 

The Company hereby
(i) waives any actual or potential conflicts of interest arising from Reed Smith LLP’s (“Reed Smith”)
concurrent representations of Roc Nation, LLC, Global Brands Group Inc. and any of their respective Affiliates, on the one hand,
and Investor, each of the Investor Directors, the SDI Adviser and any of their respective Affiliates, on the other hand, and (ii)
agrees not to seek to disqualify Reed Smith from acting as counsel to Roc Nation, LLC, Global Brands Group Inc., Investor, the
Investor Directors, the SDI Adviser or any of their respective Affiliates on the basis of any such actual or potential conflicts
of interest, in each case, subject to Reed Smith creating a customary ethical wall to separate any actual or potential conflict
matters.

 

		16.	Entire Agreement; Amendment and Waiver; Successors and Assigns.

 

This Agreement (including
its exhibits) contains the entire understanding of the Parties with respect to its subject matter. There are no restrictions, agreements,
promises, representations, warranties, covenants or undertakings between the Parties other than those expressly set forth herein.
No modifications of this Agreement can be made except in writing signed by an authorized representative of each of the Parties.
No failure on the part of any Party to exercise, and no delay in exercising, any right, power or remedy hereunder shall operate
as a waiver thereof, nor shall any single or partial exercise of such right, power or remedy by such Party preclude any other or
further exercise thereof or the exercise of any other right, power or remedy. All remedies hereunder are cumulative and are not
exclusive of any other remedies provided by law. The terms and conditions of this Agreement shall be binding upon, inure to the
benefit of, and be enforceable by the Parties and their respective successors, heirs, executors, legal representatives, and permitted
assigns. No Party shall assign this Agreement or any rights or obligations hereunder without, with respect to Investor, the prior
written consent of the Company, and with respect to the Company, the prior written consent of Investor. This Agreement is solely
for the benefit of the Parties and is not enforceable by any other persons or entities.

 

[The remainder of this page intentionally
left blank]

 

    16 

     

    

 

IN WITNESS WHEREOF,
this Agreement has been duly executed and delivered by the duly authorized signatories of the Parties as of the date hereof. 

 

	ICONIX BRAND GROUP, INC.	 
	 	 	 
	By:	/s/ Jason Schaefer	 
	Name: 	Jason Schaefer	 
	Title: 	General Counsel	 
	 	 	 
	SPORTS DIRECT INTERNATIONAL PLC	 
	 	 	 
	By:	/s/ Cameron Olsen	 
	Name: 	Cameron Olsen	 
	Title: 	Corporate Secretary	 

 

    	 

     

    

 

EXHIBIT A

[CHARTER OF THE STEERING COMMITTEE]

 

 

 

 

    	 

     

    

 

EXHIBIT B

[FORM OF CONFIDENTIALITY AGREEMENT]

 

 

 

 

    	 

     

    

 

EXHIBIT C

[FORM OF PRESS RELEASE]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00285-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00285-of-00352.parquet"}]]